Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MicOryx: FSP Vaccination in MSI-H Colorectal Cancer
NCT01461148Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2011
- Primary completion
- Mar 2015
- Countries
- 1
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Drugs
- HT001
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label, single-arm trial of HT001 in colorectal cancer (CRC). Primary endpoint: Immune response against FSP peptides. Started Aug 2011; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
FSP peptides
Vaccination with AIM2(-1), HT001(-1), and TAF1B(-1) combined with Montanide ISA-51 VG
03
Who it enrols
Patients with advanced MSI-H colorectal cancer (UICC stage III/IV) who have received or refused standard therapy, with ECOG 0-2 and adequate organ function.
04
Endpoints
Primary
Immune response against FSP peptides
Secondary
Tumor response
Safety
Beyond the preview
Go deeper on NCT01461148.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01461148.